XOMA - Utang jangka dawa xoma.com

XOMA Royalty (XOMA) relies on the expertise of a tight-knit circle of lawyers and specialized licensing experts whose loyalty is maintained through a system of partnership bonuses. The business model is based on acquiring rights to royalty payments from drug sales, which ensures exceptional margins due to the absence of manufacturing costs. The current figure is 0.14. The price action for the company shown on this chart reflects the results of diversifying its biopharmaceutical asset portfolio.

This metric aggregates all liabilities with a maturity of more than one year, reflecting the long-term debt load based on quarterly reports. This metric measures financial leverage, where reducing debt minimizes risk but limits expansion. For XOMA, which acquires royalty rights without incurring R&D costs, debt capital serves as a tool for scaling its portfolio. A time-series analysis of the firm's long-term borrowings allows for an assessment of the balance between financial stability and the pace of new asset acquisitions.